Log in

Relevant bibliographies by topics / Atorvastatin; Fenofibrate / Journal articles

To see the other types of publications on this topic, follow the link: Atorvastatin; Fenofibrate.

Journal articles on the topic 'Atorvastatin; Fenofibrate'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Atorvastatin; Fenofibrate.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Atorvastatin/fenofibrate." Reactions Weekly &NA;, no. 1304 (2010): 10–11. http://dx.doi.org/10.2165/00128415-201013040-00032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kudupudi, Chandrasekhar, and Manikandan Ayyar. "Novel Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) Method Development and Validation of Atorvastatin and Fenofibrate in Tablets." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 11, no. 02 (2020): 232–36. http://dx.doi.org/10.25258/ijpqa.11.2.7.

Full text

Abstract:

A novel, simple, selective, precise, and accurate reverse-phase high-performance liquid chromatography (RP-HPLC) gradient method was developed for the simultaneous estimation of atorvastatin and fenofibrate in the combined formulation. The drugs atorvastatin calcium and fenofibrate were separated in the presence of their impurities atorvastatin related compound H, fenofibrate related compound A, and fenofibrate related compound B. The drugs and related compounds were separated on Kromasil C18 (250 x 4.6, 5μ) with reverse-phase gradient elution. Water adjusted pH 4.0 with phosphoric acid used a

APA, Harvard, Vancouver, ISO, and other styles

3

Kudupudi, Chandrasekhar, and Manikandan Ayyar. "Novel Isocratic RP-HPLC Method Development and Validation of Rosuvastatin and Fenofibrate in Tablets." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 11, no. 03 (2020): 343–49. http://dx.doi.org/10.25258/ijpqa.11.3.7.

Full text

Abstract:

A novel, simple, selective, precise, and accurate reverse-phase high-performance liquid chromatography (RP-HPLC) gradient method was developed for the simultaneous estimation of atorvastatin and fenofibrate in the combined formulation. The drugs atorvastatin calcium and fenofibrate were separated in the presence of their impurities atorvastatin related compound H, fenofibrate related compound A, and fenofibrate related compound B. The drugs and related compounds were separated on Kromasil C18 (250 x 4.6, 5μ) with reverse-phase gradient elution. Water adjusted pH 4.0 with phosphoric acid used a

APA, Harvard, Vancouver, ISO, and other styles

4

Mondragón-García, Andrea, María Luna-Luna, Cristobal Flores-Castillo, et al. "Atorvastatin and Fenofibrate Exert Opposite Effects on the Vascularization and Characteristics of Visceral Adipose Tissue in New Zealand White Rabbits." Journal of Cardiovascular Pharmacology and Therapeutics 24, no. 6 (2019): 559–66. http://dx.doi.org/10.1177/1074248419838517.

Full text

Abstract:

Statins may precipitate the onset of type 2 diabetes (T2D) in high-risk patients. In contrast, only the subset of individuals with insulin resistance and/or diabetes receives cardiovascular benefits with fibrates. In this context, previous observations from our laboratory suggested that atorvastatin induced an increase in visceral adipose tissue (VAT), whereas fenofibrate had the opposite effects in rabbits. Therefore, we determined the mass, morphology, and vascularization of VAT in New Zealand white rabbits (n = 6/group) that received 0.33 or 2.6 mg/kg/d of atorvastatin or fenofibrate, respe

APA, Harvard, Vancouver, ISO, and other styles

5

Bhinge, S. D., S. M. Malipatil, A. Jondhale, R. Hirave, and A. S. Savali. "A New Approach to the RP-HPLC Method for Simultaneous Estimation of Atorvastatin Calcium and Fenofibrate in Pharmaceutical Dosage Forms." E-Journal of Chemistry 9, no. 3 (2012): 1223–29. http://dx.doi.org/10.1155/2012/171250.

Full text

Abstract:

The present manuscript describes the development and validation of an isocratic reverse phase high-performance liquid chromatographic (RP-HPLC) method for the estimation of Atorvastatin calcium and Fenofibrate in raw material and tablet. Atorvastatin Calcium, Fenofibrate and Diclofenac (internal standard) were well separated using a reversed phase column and mobile phase consisting of acetonitrile:KH2PO4(50 mM) (72:28v/v) (pH 4.1). The mobile phase was pumped at 1.0 mL/min flow rate and atorvastatin calcium and fenofibrate were detected by UV-Vis detection at 260 nm. The retention time for ato

APA, Harvard, Vancouver, ISO, and other styles

6

Manoj, Kumar, Kumar Gupta Chandresh, Kumar Gyanendra, and Verma Laxman. "Assessing the Impact of Body Mass Index on Lipid Lowering Treatment Choice: Fenofibrate vs. Atorvastatin in Atherogenic Dyslipidemia Patients." International Journal of Pharmaceutical and Clinical Research 16, no. 5 (2024): 633–39. https://doi.org/10.5281/zenodo.11408968.

Full text

Abstract:

The impact of Body Mass Index (BMI) on the choice between Fenofibrate and Atorvastatin as treatments for patients with atherogenic dyslipidemia (AD). A total of 156 patients with AD were split into two groups, one receiving Atorvastatin and the other receiving Fenofibrate for a period of three months. The initial results indicated that BMI plays a significant role in the decision of which lipid-lowering treatment to use for patients with AD. An analysis of the lipid profile among different BMI categories revealed that atorvastatin was effective in reducing LDL-C, TC, and TG levels, while fenof

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Atorvastatin/fenofibrate/pravastatin." Reactions Weekly &NA;, no. 1216 (2008): 10. http://dx.doi.org/10.2165/00128415-200812160-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Flores-Castillo, Cristóbal, María Luna-Luna, Elizabeth Carreón-Torres, et al. "Atorvastatin and Fenofibrate Increase the Content of Unsaturated Acyl Chains in HDL and Modify In Vivo Kinetics of HDL-Cholesteryl Esters in New Zealand White Rabbits." International Journal of Molecular Sciences 20, no. 10 (2019): 2521. http://dx.doi.org/10.3390/ijms20102521.

Full text

Abstract:

Previous studies demonstrated modifications of high-density lipoproteins (HDL) structure and apolipoprotein (apo) A-I catabolism induced by the atorvastatin and fenofibrate combination. However, it remains unknown whether such structural and metabolic changes of HDL were related to an improvement of the HDL-cholesteryl esters (HDL-CE) metabolism. Therefore, we determined the structure of HDL and performed kinetic studies of HDL-CE radiolabeled with tritium in rabbits treated with atorvastatin, fenofibrate, and a combination of both drugs. The atorvastatin and fenofibrate combination increased

APA, Harvard, Vancouver, ISO, and other styles

9

ALI, IRSHAD, BK DUBEY, DEEPAK KUMAR BASEDIA, PRABHAT KUMAR JAIN, SUNIL SHAH, and VIVEK SINGH THAKUR. "ECO-FRIENDLY METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF FENOFIBRATE AND ATORVASTATIN IN MARKETED FORMULATION." Current Research in Pharmaceutical Sciences 13, no. 4 (2024): 167–71. http://dx.doi.org/10.24092/crps.2023.130402.

Full text

Abstract:

This study focuses on the development and validation of an eco-friendly analytical method for the simultaneous estimation of Fenofibrate (FNF) and Atorvastatin (ATV) in a marketed formulation. The stability of both drugs was evaluated using a mixed hydrotropic solution of 2M Ammonium Acetate and 2M Sodium Citrate (1:1). This work focuses on the development and validation of an eco-friendly method for the simultaneous estimation of Fenofibrate and Atorvastatin in a marketed formulation. The stability of both drugs in a mixed hydrotropic solution was confirmed, and the method exhibited good line

APA, Harvard, Vancouver, ISO, and other styles

10

Arora, Ankit, Navyug Raj Singh, and Rajiv Sharma. "Comparative study of efficacy and safety of omega 3 fatty acids and fenofibrate with background atorvastatin therapy in patients of atherogenic dyslipidaemia." International Journal of Basic & Clinical Pharmacology 8, no. 6 (2019): 1145. http://dx.doi.org/10.18203/2319-2003.ijbcp20192176.

Full text

Abstract:

Background: Trials of atorvastatin combined either with fenofibrate or with omega-3 fatty acids (O3FA) have shown promising results in atherogenic dyslipidemia but there are very few studies where both these TGs lowering agents have been compared with each other. This study was conducted to compare efficacy and safety of these two agents on lipid profile of patients of atherogenic dyslipidaemia on background statin therapy and also to monitor effects of these interventions on serum uric acid (SUA) levels.Methods: About 90 patients of dyslipidemia were randomised to 3 groups and received O3FA (

APA, Harvard, Vancouver, ISO, and other styles

11

Patel, Archita, Chhaya MaCwana, Vishal Parmar, and Samir Patel. "Simultaneous Determination of Atorvastatin Calcium, Ezetimibe, and Fenofibrate in a Tablet Formulation by HPLC." Journal of AOAC INTERNATIONAL 95, no. 2 (2012): 419–23. http://dx.doi.org/10.5740/jaoacint.1-095.

Full text

Abstract:

Abstract An accurate, simple, reproducible, and sensitive HPLC method was developed and validated for the simultaneous determination of atorvastatin calcium, ezetimibe, and fenofibrate in a tablet formulation. The analyses were performed on an RP C18 column, 150 × 4.60 mm id, 5 μm particle size. The mobile phase methanol–acetonitrile–water (76 + 13 + 11, v/v/v), was pumped at a constant flow rate of 1 mL/min. UV detection was performed at 253 nm. Retention times of atorvastatin calcium, ezetimibe, and fenofibrate were found to be 2.25, 3.68, and 6.41 min, respectively. The method was validated

APA, Harvard, Vancouver, ISO, and other styles

12

Malik, J. "Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial — FAT)." Cardiovascular Research 52, no. 2 (2001): 290–98. http://dx.doi.org/10.1016/s0008-6363(01)00382-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Maminakis, Chris, Arin C. Whitman, and Nahida Islam. "Bexarotene-Induced Hypertriglyceridemia: A Case Report." Case Reports in Oncology 11, no. 1 (2018): 234–38. http://dx.doi.org/10.1159/000488447.

Full text

Abstract:

We present a case of a patient with cutaneous T-cell lymphoma started on bexarotene 300 mg/m2 due to progressing disease. The patient experienced good clinical response, but unfortunately, she developed rapid and profound hypertriglyceridemia. Although hypertriglyceridemia occurs in high incidence with bexarotene therapy, management recommendations are scarce. Due to the rise in triglycerides, atorvastatin 10 mg daily was initiated in combination with fenofibrate 120 mg daily. Triglycerides continued to increase, so the patient was instructed to take atorvastatin 40 mg, fenofibrate 120 mg, and

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Choline fenofibrate + atorvastatin combo regulates lipids." Inpharma Weekly &NA;, no. 1632 (2008): 4. http://dx.doi.org/10.2165/00128413-200816320-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "A fixed combination of atorvastatin and fenofibrate appears to have benefits over atorvastatin and fenofibrate monotherapies." Inpharma Weekly &NA;, no. 1638 (2008): 4. http://dx.doi.org/10.2165/00128413-200816380-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Santhi, N., S. S Rajendran, and Akshaya Karthigeyan. "Simultaneous Estimation of Atorvastatin and Fenofibrate by HPTLC in Pharmaceutical Mixture." International Journal of Science and Research (IJSR) 10, no. 11 (2021): 1215–19. https://doi.org/10.21275/mr211123105115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Gahlot, Rahul, Sahil Kumar, Sandeep Garg, Shalini Chawla, and Bhupinder Singh Kalra. "Efficacy and safety of Saroglitazar and Fenofibrate in the treatment of diabetic dyslipidaemia: A pilot study." Indian Journal of Physiology and Pharmacology 67 (March 29, 2023): 15–20. http://dx.doi.org/10.25259/ijpp_257_2022.

Full text

Abstract:

Objectives: Diabetic dyslipidaemia (DD) is characterised by hypertriglyceridaemia and elevated or normal levels of low-density lipoprotein cholesterol and decreased levels of high-density lipoprotein cholesterol with Type 2 diabetes mellitus. Statins and anti-diabetic medication are coprescribed for optimal control. Materials and Methods: The objective of the study was to compare the safety and efficacy of Saroglitazar 4-mg and Fenofibrate 200 mg in combination with low dose Atorvastatin (10 mg) in patients with DD. Run-in period of 4 weeks for life-style and diet modification followed by 12 w

APA, Harvard, Vancouver, ISO, and other styles

18

Jain, Shilpa, and J. L. Marko. "Cost variation analysis of oral anti-dyslipidaemic drugs available in Indian pharmaceutical market." International Journal of Basic & Clinical Pharmacology 9, no. 5 (2020): 753. http://dx.doi.org/10.18203/2319-2003.ijbcp20201752.

Full text

Abstract:

Background: Dyslipidaemia is one of major risk factor contributing to cardiovascular disease, which further causes mortality and morbidity, so requires a long course of treatment. Physicians should be aware of the cost of drugs.Methods: Cost of the oral anti-dyslipidaemic drug, either as single drug or in combination manufactured by different pharmaceutical companies in the same strength and dosage form was obtained from current index of medical specialities (CIMS) April-July 2019. The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical compani

APA, Harvard, Vancouver, ISO, and other styles

19

Krysiak, Robert, Witold Szkróbka, and Bogusław Okopień. "The Effect of Hypolipidemic Agents on Thyroid Autoimmunity in Women with Hashimoto’s Thyroiditis Treated with Levothyroxine and Selenomethionine." Experimental and Clinical Endocrinology & Diabetes 126, no. 05 (2017): 321–26. http://dx.doi.org/10.1055/s-0043-120342.

Full text

Abstract:

Abstract Background Levothyroxine and selenomethionine were found to reduce thyroid antibody titers in patients with Hashimoto’s thyroiditis. The same effect was produced by intensive statin therapy. The aim of the present study was to assess whether hypolipidemic agents modulate the impact of thyroid hormone supplementation and selenomethionine on thyroid autoimmunity. Methods The study included 62 women with Hashimoto's thyroiditis treated for at least 6 months with levothyroxine and selenomethionine. On the basis of plasma lipids, women were divided into three groups: women with isolated hy

APA, Harvard, Vancouver, ISO, and other styles

20

Kumar, Manoj, Avivar Awasthi, Deep Dutta, Ameya Joshi, and Meha Sharma. "Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis." Indian Journal of Endocrinology and Metabolism 29, no. 3 (2025): 268–75. https://doi.org/10.4103/ijem.ijem_528_24.

Full text

Abstract:

Abstract Introduction: Fenofibrate forms the standard of care for managing hypertriglyceridemia. Many of these patients have associated metabolic dysfunction-associated steatotic liver disease (MASLD). No systematic review and meta-analysis (SRM) has analysed the impact of fenofibrate in MASLD. Hence, we undertook this SRM. Methods: Electronic databases were searched for randomised controlled trials (RCTs) involving MASLD patients receiving fenofibrate as an intervention and placebo/active comparator as control. The primary outcome was changes in alanine aminotransferase (ALT) and aspartate am

APA, Harvard, Vancouver, ISO, and other styles

21

Gopalakrishna, Ashika Arka, Noah M. Bose, and Sharon M. Stanly. "Cost variation analysis of statins available in India." International Journal of Basic & Clinical Pharmacology 10, no. 11 (2021): 1259. http://dx.doi.org/10.18203/2319-2003.ijbcp20214114.

Full text

Abstract:

Background: The current study aimed to find out the percentage cost variation among the various brands of statins marketed in India. Statins are HMG-CoA reductase inhibitors which are widely prescribed as blood cholesterol lowering agents and hence reduce illness and mortality in those who are at high risk of cardiovascular disease. There are numerous brands of statins are marketed in India.Methods: Cost of a particular drug manufactured by different companies in the same strength and the dosage form was obtained from the price list provided by the pharmaceutical companies in current index of

APA, Harvard, Vancouver, ISO, and other styles

22

Al-Tannak, Naser F., and Ahmed Hemdan. "Eco-Friendly Separation of Antihyperlipidemic Combination Using UHPLC Particle-Packed and Monolithic Columns by Applying Green Analytical Chemistry Principles." Separations 8, no. 12 (2021): 246. http://dx.doi.org/10.3390/separations8120246.

Full text

Abstract:

Efficient separation of pharmaceuticals and metabolites with the adequate resolution is a key factor in choosing the most suitable chromatographic method. For quality control, the analysis time is a key factor, especially in pharmacokinetic studies. High back pressure is considered as one of the most important factors in chromatography’s flow control, especially in UHPLC. The separation of the anti-hyperlipidemic mixtures was carried out using two columns: a column silica-based particle packed UHPLC and a monolithic column. The systematic suitability of the two columns was compared for the sep

APA, Harvard, Vancouver, ISO, and other styles

23

Whitfield, Lloyd R., Anthony R. Porcari, Christine Alvey, Robert Abel, William Bullen, and Daniel Hartman. "Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin." Journal of Clinical Pharmacology 51, no. 3 (2011): 378–88. http://dx.doi.org/10.1177/0091270010366446.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Farooq, Bakhtawar, Rafay-Ur-Rehman Cheema, Zahid Habib Qureshi, Nabeela Yasmeen, and Ejaz Hussain Sahu. "The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia." Life and Science 5, no. 2 (2024): 07. http://dx.doi.org/10.37185/lns.1.1.632.

Full text

Abstract:

Objective: This study aimed to evaluate the efficacy and safety of saroglitazar and fenofibrate in treatingdiabetic dyslipidemia.Study Design: Comparative cross-sectional study.Place and Duration of Study: The study was conducted at the Department of Biochemistry, Nishtar MedicalUniversity and Hospital Multan, Pakistan over 12 months from January 2021 to January 2022.Methods: Following a 4-week run-in phase, sixty newly diagnosed patients with a previous diagnosis ofdiabetes and dyslipidemia were included. Eligible participants were aged 18-65 years, with fasting triglyceride(TG) levels >20

APA, Harvard, Vancouver, ISO, and other styles

25

Shinde, Meghna, and Anjali Kushwah. "A Pharmacoeconomic Comparison of Cost Variation among Hypolipidemic Drugs Available in Indian Market." Pharmacology and Clinical Pharmacy Research 6, no. 3 (2021): 112. http://dx.doi.org/10.15416/pcpr.v6i3.32488.

Full text

Abstract:

Hyperlipidemia is a major cause of atherosclerotic coronary and cerebrovascular disorders affecting a large Indian population. The cost of various hypolipidemic drugs that are used for the prevention and treatment of these afflictions largely varies in the Indian pharmaceutical market. Our study aimed to evaluate the cost variation of different brands of hypolipidemic drugs and to compare the branded prices with their corresponding generic and ceiling prices. The costs of various drugs were procured from the latest issue of the “Drug Today” from October to November 2020 edition which is a dire

APA, Harvard, Vancouver, ISO, and other styles

26

Chatley, P., D. K. Badyal, R. Calton, and P. P. Khosla. "Combination therapy of low dose atorvastatin and fenofibrate in mixed hyperlipidemia." Methods and Findings in Experimental and Clinical Pharmacology 29, no. 3 (2007): 217. http://dx.doi.org/10.1358/mf.2007.29.3.1075363.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Macwana, Chhaya R., Archita J. Patel, Vishal M. Parmar, and Samir G. Patel. "SIMULTANEOUS HPTLC ANALYSIS OF ATORVASTATIN CALCIUM, EZETIMIBE, AND FENOFIBRATE IN TABLET." Journal of Liquid Chromatography & Related Technologies 35, no. 4 (2012): 524–32. http://dx.doi.org/10.1080/10826076.2011.601502.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Dizaye, Kawa, and Sundus Ahmed. "Combination of atorvastatin and fenofibrate altered androgenic activities of male rats." Zanco Journal of Medical Sciences 23, no. 2 (2019): 273–82. http://dx.doi.org/10.15218/zjms.2019.034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Roopmani, Purandhi, and Uma Maheswari Krishnan. "Harnessing the pleiotropic effects of atorvastatin-fenofibrate combination for cardiovascular stents." Materials Science and Engineering: C 92 (November 2018): 875–91. http://dx.doi.org/10.1016/j.msec.2018.07.048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Farnier, M., P. Maigret, and G. Turpin. "Efficacy of atorvastatin compared with fenofibrate in patients with combined hyperlipidemia." Atherosclerosis 151, no. 1 (2000): 51. http://dx.doi.org/10.1016/s0021-9150(00)80231-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

BP, Disha, Rina N. Desai, Anand IS, and Patel CN. "Comparative Study of Atorvastatin plus Fenofibrate versus Atorvastatin alone for its safety and efficacy in Hyperlipidemic patients." Indian Journal of Pharmacy Practice 7, no. 4 (2015): 39–45. http://dx.doi.org/10.5530/ijopp.7.4.8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Milionis, Haralampos J., Eleni T. Bairaktari, Evangelos N. Liberopoulos, and Moses S. Elisaf. "Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia." American Journal of Cardiology 88, no. 2 (2001): 203. http://dx.doi.org/10.1016/s0002-9149(01)01660-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Derosa, G., S. Salvadeo, I. Ferrari, and A. Cicero. "Abstract: P782 EFFECTS OF ATORVASTATIN-FENOFIBRATE COMBINATION COMPARED TO ATORVASTATIN MONOTHERAPY ON LIPID PROFILE IN PATIENTS WITH COMBINED DYSLIPIDEMIA." Atherosclerosis Supplements 10, no. 2 (2009): e958. http://dx.doi.org/10.1016/s1567-5688(09)70938-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Atorvastatin and simvastatin, unlike fenofibrate, have a neutral effect on serum homocysteine levels,." Inpharma Weekly &NA;, no. 1404 (2003): 18. http://dx.doi.org/10.2165/00128413-200314040-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Dixit, Rohit, and Shankar Jagan. "Comparative Study of Atorvastatin and Rosuvastatin in Combination with Fenofibrate in mixed Hyperlipidemia." International Journal of Pharmacology and Clinical Sciences 5, no. 1 (2016): 25–31. http://dx.doi.org/10.5530/ijpcs.5.1.5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Melenovsky, Vojtech, Dan Wichterle, Jan Simek, et al. "Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia." American Journal of Cardiology 92, no. 3 (2003): 337–41. http://dx.doi.org/10.1016/s0002-9149(03)00643-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Bhinge, Somnath D., Sharangauda M. Malipatil, Abhijeet Jondhale, and Anil S. Savali. "Simultaneous Estimation of Atorvastatin Calcium and Fenofibrate in Rabbit Plasma by RP-HPLC." Asian Journal of Chemistry 25, no. 2 (2013): 981–85. http://dx.doi.org/10.14233/ajchem.2013.13310.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Davidson, Michael H., Michael W. Rooney, Joan Drucker, H. Eugene Griffin, Sonia Oosman, and Michael Beckert. "Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group study." Clinical Therapeutics 31, no. 12 (2009): 2824–38. http://dx.doi.org/10.1016/j.clinthera.2009.12.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Korany, Mohamed A., Ismail I. Hewala, and Karim M. Abdel-Hay. "Determination of Etofibrate, Fenofibrate, and Atorvastatin in Pharmaceutical Preparations and Plasma Using Differential Pulse Polarographic and Square Wave Voltammetric Techniques." Journal of AOAC INTERNATIONAL 91, no. 5 (2008): 1051–58. http://dx.doi.org/10.1093/jaoac/91.5.1051.

Full text

Abstract:

Abstract Etofibrate, fenofibrate, and atorvastatin were determined in their pharmaceutical preparations and human plasma using differential pulse polarographic and square wave voltammetric techniques by reduction at a dropping-mercury working electrode versus Ag/AgCl reference electrode. The reversibility of the electrode reactions was tested using cyclic voltammetry, and they were found to be irreversible reduction reactions. Optimum conditions such as pH, scan rate, and pulse amplitude were studied, and validation of the proposed methods was performed. The proposed methods proved to be accur

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Coadministration of fenofibrate does not have a significant effect on the pharmacokinetics of atorvastatin." Reactions Weekly &NA;, no. 1306 (2010): 6. http://dx.doi.org/10.2165/00128415-201013060-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Iovine, C., S. Lilli, A. Gentile, et al. "Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia." European Journal of Clinical Investigation 36, no. 8 (2006): 560–65. http://dx.doi.org/10.1111/j.1365-2362.2006.01677.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Nakarani, Naresh V., Kashyap K. Bhatt, Rutva D. Patel, and Hemaxi S. Bhatt. "Estimation of Atorvastatin Calcium and Fenofibrate in Tablets by Derivative Spectrophotometry and Liquid Chromatography." Journal of AOAC INTERNATIONAL 90, no. 3 (2007): 700–705. http://dx.doi.org/10.1093/jaoac/90.3.700.

Full text

Abstract:

Abstract Two simple and accurate methods to determine atorvastatin calcium (ATO) and fenofibrate (FEN) in combined dosage forms were developed using second-derivative spectrophotometry and reversed-phase liquid chromatography (LC). ATO and FEN in combined preparations (tablets) were quantitated using the second-derivative responses at 245.64 nm for ATO and 289.56 nm for FEN in spectra of their solution in methanol. The calibration curves were linear [correlation coefficient (r) = 0.9992 for ATO and 0.9995 for FEN] in the concentration range of 315 g/mL for ATO and FEN. In the LC method, analys

APA, Harvard, Vancouver, ISO, and other styles

43

Ghosh, Sanjib, Sweata Sarkar, and Maharaj Biswas. "Fenofibrate ameliorated atorvastatin and piperine-induced ROS mediated reproductive toxicity in male Wistar rats." Toxicology Reports 14 (June 2025): 101861. https://doi.org/10.1016/j.toxrep.2024.101861.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Delaval, D., J. P. Després, and H. Salomon. "Micronized fenofibrate compared to atorvastatin in low HDL-cholesterol patients (<40 mg/dl)." Atherosclerosis Supplements 2, no. 2 (2001): 48–49. http://dx.doi.org/10.1016/s1567-5688(01)80061-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Koh, Kwang Kon, Michael J. Quon, Seung Hwan Han, et al. "Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia." Journal of the American College of Cardiology 45, no. 10 (2005): 1649–53. http://dx.doi.org/10.1016/j.jacc.2005.02.052.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Koh, K. K., M. J. Quon, and S. H. Han. "Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia." ACC Current Journal Review 14, no. 9 (2005): 26–27. http://dx.doi.org/10.1016/j.accreview.2005.08.204.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

BUDIN, KAMSIA, NUR ZAIDA ZAHARI, SURIANI HASSAN, and ALYA AFIQAH SHAKAR. "PRIORITISATION OF ANTILIPIDEMIC IN SURFACE WATER OF MALAYSIA USING A RISK-BASED APPROACH." JOURNAL OF SUSTAINABILITY SCIENCE AND MANAGEMENT 18, no. 5 (2023): 67–74. http://dx.doi.org/10.46754/jssm.2023.05.005.

Full text

Abstract:

Pharmaceutical is essential for modern human society, however when they are released into the environment, they may harm non-target organisms. This study investigates the potential of antilipidemic to exert biological effects on aquatic organisms by determining the risk of antilipidemic to algae, fish, and invertebrates. Predicted Environmental Concentrations (PECs) were determined from fractional excretion and emission from wastewater treatment of antilipidemic which was obtained from numerous trusted sources. The Risk Quotient (RQ) was defined from PEC/ PNEC (Predicted No Effect Concentratio

APA, Harvard, Vancouver, ISO, and other styles

48

Sriram, A* Dhanapal C.K and Junior Sundresh. N. "PRESCRIBING PATTERN OF ANTIHYPERTENSIVE INVOLVED IN HYPERTENSIVE PATIENTS IN ATERTIARY CARE TEACHING HOSPITAL." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 05 (2018): 3638–42. https://doi.org/10.5281/zenodo.1244666.

Full text

Abstract:

Hypertension is one of the major global risk factor among the cardiovascular diseases leads to increase in morbidity, mortality rate as well as health burdens1 . In 2020 it has been estimated that 1.32 billion world populations will suffer from hypertension. As per current prevalence rate on hypertension in India is 18.52 and ranks at 67 among worldwide. WHO statistics reported that death rate among hypertensive patients in India was 1.79%. To determine the prescribing trends of antihypertensives involved in patients with hypertension. Out of 73 encounters, 43 (59%) males and 32(41%) females w

APA, Harvard, Vancouver, ISO, and other styles

49

Goosen, Theunis C., Jonathan N. Bauman, John A. Davis, et al. "Atorvastatin Glucuronidation Is Minimally and Nonselectively Inhibited by the Fibrates Gemfibrozil, Fenofibrate, and Fenofibric Acid." Drug Metabolism and Disposition 35, no. 8 (2007): 1315–24. http://dx.doi.org/10.1124/dmd.107.015230.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Shanbag, Niteesh, Vijay Naik, and Bharathraj M.Y. "COMPARATIVE STUDY TO EVALUATE LIPID-LOWERING EFFECT OF FENOFIBRATE VERSUS ATORVASTATIN IN PATIENTS WITH HYPERTRIGLYCERIDAEMIA." Journal of Evidence Based Medicine and Healthcare 4, no. 26 (2017): 1542–46. http://dx.doi.org/10.18410/jebmh/2017/301.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!